Revolution Medicines, Inc. filings document a late-stage clinical oncology company focused on RAS-addicted cancers and RAS(ON) inhibitors. Its Form 8-K reports include financial results, clinical-program updates for daraxonrasib and other pipeline candidates, regulatory-related disclosures and material events tied to corporate progress.
The company’s SEC record also covers proxy governance, annual meeting matters, executive compensation, registered securities and capital-structure changes. Disclosures identify Nasdaq-listed common stock and warrants, and material-agreement filings describe convertible senior notes due 2033, related indenture terms and other financing arrangements used to support research and development, administrative expenses and potential commercialization activities.
Revolution Medicines, Inc. (RVMD) notice reports a proposed sale under Rule 144 of 150,000 common shares through Morgan Stanley Smith Barney. The filing shows the shares were acquired and will be sold on 09/11/2025 via exercise of stock options, with cash payment at exercise. The filing lists an aggregate market value of $6,067,500 for the shares and reports 186,933,190 shares outstanding, implying the 150,000-share block represents about 0.08% of outstanding common stock. The filer also disclosed a prior sale on 06/16/2025 of 4,289 shares for gross proceeds of $170,830.87. The notice contains broker details and the filer’s signature attestations required under Rule 144.
Revolution Medicines (RVMD) reported clinical updates for daraxonrasib in RAS-mutant pancreatic ductal adenocarcinoma (PDAC). Safety data as of a June 30, 2025 second-line cutoff and a July 28, 2025 first-line cutoff show the most common treatment-related adverse events were rash and gastrointestinal toxicities. Results from the RMC-6236-001 and RMC-GI-102 studies support the company’s plan to start RASolute 303, a global randomized Phase 3 trial comparing daraxonrasib monotherapy and daraxonrasib plus GnP against GnP alone in first-line metastatic RAS-mutant PDAC.
The filing reiterates standard forward-looking risk disclosures about clinical development, regulatory review, manufacturing, intellectual property, third-party reliance, capital sufficiency, and geopolitical or pandemic effects.
Revolution Medicines CFO Jack Anders reported multiple transactions under a 10b5-1 plan on September 2-3, 2025. The filings show option exercises and open-market sales and purchases: Mr. Anders exercised stock options at strike prices of $2.68, $4.73 and $17 and acquired 9,200 shares through option exercises and purchase transactions at prices between $2.68 and $17. He sold a total of 10,000 shares in multiple trades at weighted-average sale prices of approximately $40.02 and $40.1742. After these transactions he beneficially owned 113,314 shares (which include 54,213 RSUs) and held stock options exercisable into 15,418 shares. The transactions were made pursuant to a 10b5-1 trading plan adopted December 16, 2024.
Form 144 notice for Revolution Medicines, Inc. (RVMD) reporting a proposed sale of 10,000 common shares acquired and to be sold on 09/02/2025 following an exercise of stock options. The broker listed is Morgan Stanley Smith Barney LLC and the aggregate market value of the shares at filing is $379,700.00. The filing states the issuer has 186,933,190 shares outstanding. The seller previously disposed of 2,170 common shares on 06/16/2025 for $86,431.10. The filer affirms no undisclosed material adverse information and includes standard Rule 10b5-1/attestation language.
Baker Bros. Advisors and related persons report beneficial ownership of 9,364,972 shares of Revolution Medicines, Inc. common stock, representing 5.0% of 186,901,268 shares outstanding as of June 30, 2025. The holdings are held through two funds: 667, L.P. (0.4%) and Baker Brothers Life Sciences, L.P. (4.6%). The filing states the Adviser has sole voting and dispositive power over the funds' securities under management agreements and that certain prefunded warrants exist but cannot currently be exercised because of a 4.99% ownership cap on exercise.
Janus Henderson Group plc reports a passive, non-controlling stake in Revolution Medicines common stock, with disclosed shared voting and dispositive power in the range of 10.45–10.59 million shares, representing about 5.6%–5.7% of the class. The filing identifies both a group-level beneficial figure of 10,590,727 shares (5.7%) and a related subsidiary position of 10,445,374 shares (5.6%), indicating Janus Henderson exercises shared voting and disposition rights over these holdings.
The statement certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing also includes a power-of-attorney authorizing compliance signatories to execute and amend related ownership reports on the company's behalf.